Add Formweb to your mobile device
Search results for:
natalizumab
natalizumab
Last updated: Apr. 28, 2026
- Black Box Warning: Progressive multifocal leukoencephalopathy (PML)
- REMS: Tyruko-FDA REMS Info
- REMS: Tysabri-FDA REMS Info
- REMS: Legacy Health REMS Requirements-Natalizumab
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader. See the review for details.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.
The goal of the Tysabri REMS is to mitigate the risk progressive multifocal leukoencephalophy (PML), and includes health care provider, patient, pharmacy, infusion sites and wholesaler-distributor requirements for dispensing.
See Legacy Health REMS Requirements for detail.